ConductScience.org, home

Paper36969501

Risk factors of significant relapse and appropriate maintenance therapy strategy in SLE-associated immune thrombocytopenia.

Li HJ and 4 others. Ther Adv Chronic Dis, 2023. Cited by 6 papers, by iCite.

Cite this record

ConductScience Library. Risk factors of significant relapse and appropriate maintenance therapy strategy in SLE-associated immune thrombocytopenia. Papers, record 36969501. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36969501

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Risk factors of significant relapse and appropriate maintenance therapy strategy in SLE-associated immune thrombocytopenia.
PubMed
Journal
Ther Adv Chronic Dis
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
6
iCite
Relative citation ratio, by iCite
0.94
iCite
Revised in PubMed
2024-09-14
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Li HJHe-Junhttps://orcid.org/0000-0001-9179-8887
2Zheng YQYi-Qing
3Chen LLing
4Lin SPShun-Ping
5Zheng XXXiang-Xiong

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References26

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127933196Independent association of glucocorticoids with damage accrual in SLE.Lupus Sci Med2016https://conductscience.org/library/papers/27933196PubMed
211824975Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases.J Rheumatol2002https://conductscience.org/library/papers/11824975PubMed
326554745Analysis of Complete Remission in Systemic Lupus Erythematosus Patients Over a 32-Year Period.Arthritis Care Res (Hoboken)2016https://conductscience.org/library/papers/26554745PubMed
424254965Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies.Am J Hematol2014https://conductscience.org/library/papers/24254965PubMed
533709836Which patients with systemic lupus erythematosus in remission can withdraw low dose steroids? Results from a single inception cohort study.Lupus2021https://conductscience.org/library/papers/33709836PubMed
631852672Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial.Ann Rheum Dis2020https://conductscience.org/library/papers/31852672PubMed
734556256KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.Kidney Int2021https://conductscience.org/library/papers/34556256PubMed
8348193882021 DORIS definition of remission in SLE: final recommendations from an international task force.Lupus Sci Med2021https://conductscience.org/library/papers/34819388PubMed
931945156Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866.Blood Adv2020https://conductscience.org/library/papers/31945156PubMed
1029755993The Role of Hydroxychloroquine as a Steroid-sparing Agent in the Treatment of Immune Thrombocytopenia: A Review of the Literature.J Res Pharm Pract2018https://conductscience.org/library/papers/29755993PubMed
1128013208It hasn't gone away: the problem of glucocorticoid use in lupus remains.Rheumatology (Oxford)2017https://conductscience.org/library/papers/28013208PubMed
1226871854Thrombocytopenia in Systemic Lupus Erythematosus: Clinical Manifestations, Treatment, and Prognosis in 230 Patients.Medicine (Baltimore)2016https://conductscience.org/library/papers/26871854PubMed
1334996857Risk factors of flare in patients with systemic lupus erythematosus after glucocorticoids withdrawal. A systematic review and meta-analysis.Lupus Sci Med2022https://conductscience.org/library/papers/34996857PubMed
1416567353Thrombocytopaenia in lupus as a marker of adverse outcome--seeking Ariadne's thread.Rheumatology (Oxford)2006https://conductscience.org/library/papers/16567353PubMed
15309267222019 update of the EULAR recommendations for the management of systemic lupus erythematosus.Ann Rheum Dis2019https://conductscience.org/library/papers/30926722PubMed
1635412598Low-dose glucocorticoids withdrawn in systemic lupus erythematosus: a desirable and attainable goal.Rheumatology (Oxford)2022https://conductscience.org/library/papers/35412598PubMed
1729251660Epidemiology of systemic lupus erythematosus: an update.Curr Opin Rheumatol2018https://conductscience.org/library/papers/29251660PubMed
1827558987Remission in systemic lupus erythematosus: durable remission is rare.Ann Rheum Dis2017https://conductscience.org/library/papers/27558987PubMed
1922553077Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.Arthritis Rheum2012https://conductscience.org/library/papers/22553077PubMed
2029856800Efficacy and tolerability of old and new drugs used in the treatment of immune thrombocytopenia: Results from a long-term observation in clinical practice.PLoS One2018https://conductscience.org/library/papers/29856800PubMed

See all 26 referencesDownload CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.

PMIDTitleJournalYearIn PapersSource
42956009Low-level proteinuria at the initial diagnosis of systemic lupus erythematosus significantly increases the risk of developing proteinuria-predominant lupus nephritis.PLoS One2026https://conductscience.org/library/papers/42956009PubMed
41782905Efficacy and safety of immunosuppressive therapy in connective tissue disease-related immune thrombocytopenia: a systematic review and meta-analysis.Ther Adv Hematol2026https://conductscience.org/library/papers/41782905PubMed
40799655The predictive value of NLR, SII, and complement 3 in treatment response for systemic lupus erythematosus with immune thrombocytopenia.Front Immunol2025https://conductscience.org/library/papers/40799655PubMed
39627479Immune thrombocytopenia in patients with systemic lupus erythematosus.Clin Rheumatol2025https://conductscience.org/library/papers/39627479PubMed
38916764Description of therapeutic strategies in severe systemic lupus erythematosus-associated immune thrombocytopenia: a retrospective cohort study of response and relapse.Clin Rheumatol2024https://conductscience.org/library/papers/38916764PubMed
38711668Advancements on the impact of hydroxychloroquine in systemic lupus erythematosus.Heliyon2024https://conductscience.org/library/papers/38711668PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ANXA13312PubTator's text mininghttps://conductscience.org/library/genes/312NCBI Gene
IL113589PubTator's text mininghttps://conductscience.org/library/genes/3589NCBI Gene
THPO7066PubTator's text mininghttps://conductscience.org/library/genes/7066NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36969501

GET https://conductscience.org/api/papers/v1/36969501/references?page=2